Navigation Links
Key Stakeholders to Discuss Regulatory Issues Related to the Use of Study Endpoints in Multinational Clinical Trials
Date:9/2/2009

The Drug Information Association (DIA) Study Endpoints Special Interest Area Community (SIAC) will host Measuring Study Endpoints in Multinational Clinical Trials: Outcomes Reported from the Viewpoint of the Clinician, Patient, and Caregiver from October 26-27, 2009 in New Orleans, LA.

Horsham, PA (Vocus) September 2, 2009 --The Drug Information Association (DIA) Study Endpoints Special Interest Area Community (SIAC) will host Measuring Study Endpoints in Multinational Clinical Trials: Outcomes Reported from the Viewpoint of the Clinician, Patient, and Caregiver from October 26-27, 2009 in New Orleans, LA.

Representatives from industry, FDA, and EMEA will convene to discuss the scientific and regulatory issues surrounding the use of study endpoints in support of medical product labeling claims. Sessions will discuss common principles for the development and validation of all study endpoint measures and the relationships between entry criteria and outcome measurement and between different types of endpoint measures. Specific sessions include:

 
  • Defining Terms and Setting the Regulatory Context
  • Models, Measures and Claims   
  • Evaluating and Demonstrating Content Validity
  • Regulatory Perspective of Content Validity in Pediatric, Caregiver, and Clinician-Reported Outcomes
  • Practical Considerations for Multinational Clinical Trials Defining a Research Agenda for Study Endpoint Measurement and Multinational Clinical Trials
"There has been significant discussion, but little consensus with respect to a common set of best practices applicable across all types of study endpoints in clinical trials," says Laurie Burke, MPH, Capt. USPHS, Director, Study Endpoints and Labeling, Office of New Drugs, CDER, FDA. "This conference brings together key stakeholders to discuss the conceptual, measurement, and practical issues regarding study endpoints when applied to product development."

Click here to register.

About the Drug Information Association (DIA):
DIA serves more than 30,000 professionals involved in the biopharmaceutical industry and regulatory affairs worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit www.diahome.org or call 215-442-6100.

Contact:
Joe Krasowski
DIA
+1-215-293-5812

###

Read the full story at http://www.prweb.com/releases/2009/09/prweb2822344.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. ABMS and NQF Convene Summit on Enhancing Physician Performance: Stakeholders Agree Board Certification Should Play Bigger Role in Healthcare Quality Improvement
2. Patient-Centered Primary Care Collaborative Stakeholders Come to Washington, DC for July Working Meeting
3. Key Stakeholders Convene Capitol Hill Symposium To Advance Convergence of Behavioral Economics and Healthcare
4. HIMSS Electronic Health Record Association Reaches Out to Key Stakeholders on Meaningful Use of Certified EHRs
5. Major Stakeholders in Health Reform Debate Call for Greater Focus on Disease Prevention and Management in Senate Finance Committees Policy Options Paper
6. Major Stakeholders in Health Reform Debate Call for Improvements in Scoring of Congressional Health Care Proposals
7. Patient-Centered Primary Care Collaborative Stakeholders Convene in Washington, DC for Working Meeting
8. Stakeholders and public should use 20 specific health indicators
9. Leading Government and Advocacy Stakeholders Engage in Public Health Dialogue on Improving Disposal of Unused Medications
10. Newly Formed Consortium to Combat Medical Fraud Announces National Agenda to Intensify Fight Against Health Care Fraud Goals: Collaboration Across Industries; Alignment of Resources; Increased Awareness Among Public and Private Stakeholders Including Fede
11. ADA Calls for All Stakeholders to Work Together to Help Medicaid
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Key Stakeholders to Discuss Regulatory Issues Related to the Use of Study Endpoints in Multinational Clinical Trials 
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and body care ... announced the company had a successful visit to the 2017 ECRM Diet, Vitamin & ... that work in the nutritional, sports and health industries a chance to meet in ...
(Date:1/20/2017)... Florida (PRWEB) , ... January 20, 2017 , ... Lice ... head lice cases in families with school-aged children since the holiday season. , ... the holidays with their families, sharing hugs and taking photos, which is the head-to-head ...
(Date:1/20/2017)... ... ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation in a ... has been life-saving as she has been on the trial for more than six ... ovarian cancer in 2009. She underwent standard chemotherapy but a year later went to ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “Mary Magdalene: ... the mysterious life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace ... denizen, who spent her career as an educator interacting with countless women who had ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “I Forgive You”: a fine examination of ... Forgive You” is the creation of published author, Stephen Miller, who, for over ten long ... gracefully given to him. Born in Trinidad and Tobago, he has been serving the Lord ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Jan. 19, 2017 Report Details ... Alzheimer,s ... Leading Companies – our new study reveals trends, R&D ... and events affecting the Alzheimer,s disease therapeutics and diagnostics ... these key questions: - How is the Alzheimer,s disease ...
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor ... market is expected to grow at a CAGR of 27.1% ... 38.7% in the second half of the forecast period. The market ... to 2027. The market is estimated at $1,058 million in 2016, ... ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... Grothey ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... http://photos.prnewswire.com/prnh/20151014/276718LOGO) Published recently in ... the peer-reviewed journal from touchONCOLOGY, an article by ...
Breaking Medicine Technology: